A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

Japanese encephalitis (JE) live attenuated vaccine SA14-14-2 has been in use for more more than 20 years in Asia. JE vaccine SA14-14-2 is licensed in India and has been widely used since 2006. JE vaccines give protection by generating a neutralizing antibody response, but both naturally exposed persons and patients with JE also have T cell responses. Whether JE vaccine SA14-14-2 elicits T cell responses is unknown. This study tests the hypothesis that T cell responses are generated in response to JE SA14-14-2 vaccination. The aim of this study is to characterize T cell responses to JE vaccine SA14-14-2 in healthy people, and to investigate differences in T cell responses between natural exposure, vaccination and disease.

Condition or disease	Intervention/treatment	Phase
Japanese Encephalitis; Japanese Encephalitis Vaccine	Biological: Live attenuated Japanese encephalitis vaccine SA14-14-2	Phase 4

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	17 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Basic Science
Official Title:	A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2
Study Start Date :	May 2012
Actual Primary Completion Date :	October 2013
Actual Study Completion Date :	March 2014

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Vaccine; Single dose live attenuated Japanese encephalitis vaccine SA14-14-2	Biological: Live attenuated Japanese encephalitis vaccine SA14-14-2; Live attenuated Japanese encephalitis vaccine SA14-14-2

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Change in magnitude of T lymphocyte responses to live attenuated JE SA-14-14-2 vaccine over time. [ Time Frame: Week 1, week 2, week 4, week 8, 6 months ]

Secondary Outcome Measures :

1. Change in neutralizing antibody titres to live attenuated JE SA-14-14-2 vaccine over time. [ Time Frame: one month, six months and one year after vaccination ]
2. Number of participants reporting adverse events (graded in severity 1-4). [ Time Frame: one month ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 50 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion criteria:

• A male or female adult between 18 and 50 years of age.
• Written informed consent.
• Free of obvious health problems as established by medical history and history- directed physical examination before entering the study.
• Expected continuous residence in India during study period, without travel outside India
• An efficacious method of contraception must be used during the study for women of childbearing potential.

Exclusion Criteria:

• Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding administration of SA14-14-2 vaccine, or planned use during the study period.
• Chronic administration of immunosuppressants or other immune-modifying drugs within a period of six months before vaccination or at any time during the study period.
• Any confirmed or suspected immunosuppressive or immunodeficient condition.
• A family history of congenital or hereditary immunodeficiency.
• Any antiviral drug therapy within a period of six months before vaccination or at any time during the study period.
• History of significant allergic disease or reactions likely to be exacerbated by any component of the study vaccine, especially allergic disease or reactions to any previous dose of any vaccine.
• History of having received JE vaccine, yellow fever vaccine, tick-borne encephalitis vaccine or experimental flavivirus vaccine.
• History of documented JE infection.
• Detectable anti JE or West Nile neutralizing antibodies in screening tests.
• Acute disease at the time of enrollment. Entry into the study may be deferred until the illness is resolved.
• Acute or chronic, clinically significant, pulmonary, cardiovascular, hepatic, neurological or renal functional abnormality, as determined by history and physical or laboratory examination that is not controlled by drugs.
• Administration of immunoglobulins and/or any blood products within the three months preceding administration of vaccine, or planned administration during the study period.
• Seropositive for HIV, HCV or HbsAg.
• Lactation, pregnancy or intention to get pregnant.
• History of excessive alcohol consumption, drug abuse or significant psychiatric illness.
• Any other condition that in the opinion of the investigator would pose a health risk to the participant or interfere with the evaluation of the vaccine.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

India
Indian Institute of Science
Bangalore, Karnataka, India, 560 012
National Institute of Mental Health and Neurosciences
Bangalore, Karnataka, India, 560029

Sponsors and Collaborators

Indian Institute of Science

National Institute of Mental Health and Neuro Sciences, India

University of Liverpool

PATH

Wellcome Trust

Investigators

Principal Investigator:	Prof S Vijaya, PhD	Indian Institute of Science
Principal Investigator:	Dr V Ravi, MBBS MD	National Institute of Mental Health and Neuro Sciences, India

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Turtle L, Tatullo F, Bali T, Ravi V, Soni M, Chan S, Chib S, Venkataswamy MM, Fadnis P, Yaïch M, Fernandez S, Klenerman P, Satchidanandam V, Solomon T. Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area. PLoS Negl Trop Dis. 2017 Jan 30;11(1):e0005263. doi: 10.1371/journal.pntd.0005263. eCollection 2017 Jan.

Responsible Party:	Prof S Vijaya, Dr. Lance Turtle, Professor, Indian Institute of Science
ClinicalTrials.gov Identifier:	NCT01656200 History of Changes
Other Study ID Numbers:	JEV SA14-14-2/T cell/01
First Posted:	August 2, 2012
Last Update Posted:	June 11, 2014
Last Verified:	June 2014

Keywords provided by Prof S Vijaya, Dr. Lance Turtle, Indian Institute of Science:

Japanese encephalitis; Japanese encephalitis vaccine; T lymphocyte; Immune response

Additional relevant MeSH terms:

Encephalitis; Encephalitis, Japanese; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Encephalitis, Arbovirus; Arbovirus Infections; Virus Diseases; Encephalitis, Viral	Central Nervous System Viral Diseases; RNA Virus Infections; Flavivirus Infections; Flaviviridae Infections; Infectious Encephalitis; Central Nervous System Infections; Vaccines; Immunologic Factors; Physiological Effects of Drugs